Skip to main content

ADVERTISEMENT

Stenting

01/26/2016
Jonathan D. Beard, MD, was a co-applicant, participating physician and member of the Steering Committee of the International Carotid Stenting Study (ICSS). At the 2015 VEITH Symposium in New York, Vascular Disease Management spoke with Dr....
Jonathan D. Beard, MD, was a co-applicant, participating physician and member of the Steering Committee of the International Carotid Stenting Study (ICSS). At the 2015 VEITH Symposium in New York, Vascular Disease Management spoke with Dr....
Jonathan D. Beard, MD, was a...
01/26/2016
Vascular Disease Management
12/30/2015

Anvar Babaev, MD, PhD; Pawan Hari, MD; Susanna Zavlunova, MD; Anna Kurayev, MD

 

New York University Langone Medical Center, New York, New York

Anvar Babaev, MD, PhD; Pawan Hari, MD...
Stent fractures in the SFA play a modest role in the development of in-stent restenosis. In this study, a majority of patients with in-stent restenosis did not have stent fracture.
Stent fractures in the SFA play a modest role in the development of in-stent restenosis. In this study, a majority of patients with in-stent restenosis did not have stent fracture.
Stent fractures in the SFA play...
12/30/2015
Vascular Disease Management
12/30/2015

Amjad AlMahameed, MD, MPH; Craig Walker, MD

 

Cardiovascular Institute of the South, Houma, Louisiana

Amjad AlMahameed, MD, MPH; Craig Walk...
Despite new technologies and research, stent fracture continues to be a challenge faced by vascular specialists. 
Despite new technologies and research, stent fracture continues to be a challenge faced by vascular specialists. 
Despite new technologies and...
12/30/2015
Vascular Disease Management
Review
10/03/2015

Ying Huang, MD; Gustavo S. Oderich, MD; Peter Banga, MD; Leonardo Reis de Souza, MD

Division of Vascular and Endovascular Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota

Ying Huang, MD; Gustavo S. Oderich, M...
This review describes the use of covered stents in endovascular treatment of chronic mesenteric ischemia, including indications, techniques, and results.
This review describes the use of covered stents in endovascular treatment of chronic mesenteric ischemia, including indications, techniques, and results.
This review describes the use of...
10/03/2015
Vascular Disease Management
08/29/2015

Osamu Iida, MD

 

Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan

Osamu Iida, MD   Kansai Rosai Hospi...
Although endovascular therapy of femoropopliteal lesions with nitinol bare metal stents improves the relatively low primary patency rates achieved with balloon angioplasty, up to 37% of BMS-treated femoropopliteal lesions develop in-stent...
Although endovascular therapy of femoropopliteal lesions with nitinol bare metal stents improves the relatively low primary patency rates achieved with balloon angioplasty, up to 37% of BMS-treated femoropopliteal lesions develop in-stent...
Although endovascular therapy of...
08/29/2015
Vascular Disease Management
Case Report
03/27/2015

Shabnam Rashid, BSc, MBChB; Chris Bishwanauth Sawh, MBBS; Dwayne Gavin Conway, MB ChB, MD

 

Leeds Teaching Hospital, Leeds, West Yorkshire; Sheffield Teaching Hospital, Sheffield, South Yorkshire; and Pinderfields Hospital, Wakefield, West Yorkshire, United Kingdom

Shabnam Rashid, BSc, MBChB; Chris Bis...
The authors report the case of a 56-year-old male who had embolism of a fully deployed stent from the right coronary ostium to his brachial artery during percutaneous coronary intervention.
The authors report the case of a 56-year-old male who had embolism of a fully deployed stent from the right coronary ostium to his brachial artery during percutaneous coronary intervention.
The authors report the case of a...
03/27/2015
Vascular Disease Management
Original Contribution
01/09/2015

Subhash Banerjee, MD1,2;  Gene Pershwitz, MD2;  Karan Sarode, MA1,2;  Atif Mohammad, MD1,2;
Mazen S. Abu-Fadel, MD3;  Mirza S. Baig, MD1,2;  Shirling Tsai, MD1,2;  Bertis B. Little, PhD2;
Osvaldo S. Gigliotti, MD4;  Ediberto Soto-Cora, MD5;  Mazin I. Foteh, MD6;  Gerardo Rodriguez, MD7;
Andrew Klein, MD8;  Tayo Addo, MD1;  Michael Luna, MD1;  Nicolas W. Shammas, MD9;  Anand Prasad, MD10;
Emmanouil S. Brilakis, MD, PhD1,2

Subhash Banerjee, MD1,2;  Gene Pershw...
We analyzed data from the ongoing multicenter XLPAD registry to report on the use of non-stent (atherectomy ± balloon angioplasty) and stent-based treatment of superficial femoral ar-tery (SFA), popliteal, and below-the-knee (BTK) vessels in...
We analyzed data from the ongoing multicenter XLPAD registry to report on the use of non-stent (atherectomy ± balloon angioplasty) and stent-based treatment of superficial femoral ar-tery (SFA), popliteal, and below-the-knee (BTK) vessels in...
We analyzed data from the...
01/09/2015
Journal of Invasive Cardiology
Original Contribution
01/09/2015

Ajit Pal Singh, MD, DM1;  Srinivas Budanur Chikkaswamy, MD, DM1;  Soumya Patra, MD1;  Madhav Hegde, MD2;
K.S. Ravindranath, MD, DM1;  Mahimarangaiha Jayaranganath, MD, DM3;  Cholenahally Nanjappa Manjunath, MD, DM1

Ajit Pal Singh, MD, DM1;  Srinivas Bu...
Takayasu’s arteritis (TA) is a rare inflammatory, granulomatous vasculitis primarily involving the aorta and its major branches. This study analyzes and describes the clinical features, angiographic profile, and endovascular interventions in...
Takayasu’s arteritis (TA) is a rare inflammatory, granulomatous vasculitis primarily involving the aorta and its major branches. This study analyzes and describes the clinical features, angiographic profile, and endovascular interventions in...
Takayasu’s arteritis (TA) is a...
01/09/2015
Journal of Invasive Cardiology
Clinical Editor's Corner
11/05/2014

Morton Kern, MD

Morton Kern, MD
Given what we now understand about closure devices and femoral angiography, I found it strange that this question would come up, but I put it out to my colleagues on the “Cath List” to see what the conversation might be. 
Given what we now understand about closure devices and femoral angiography, I found it strange that this question would come up, but I put it out to my colleagues on the “Cath List” to see what the conversation might be. 
Given what we now understand...
11/05/2014
Cath Lab Digest
10/27/2014

Rigved V. Tadwalkar, MD, MS and Michael S. Lee, MD

Rigved V. Tadwalkar, MD, MS and Micha...
Cardiac allograft vasculopathy (CAV) is an immunologically-mediated phenomenon that occurs in up to 50% of patients surviving to 10 years post orthotopic heart transplant. While the pediatric subgroup of OHT recipients has a lower overall...
Cardiac allograft vasculopathy (CAV) is an immunologically-mediated phenomenon that occurs in up to 50% of patients surviving to 10 years post orthotopic heart transplant. While the pediatric subgroup of OHT recipients has a lower overall...
Cardiac allograft vasculopathy...
10/27/2014
Journal of Invasive Cardiology